Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2019 07:00 ET | Source: Breathtec Biomedical Inc.

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease

VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...